View Older Stories View More Recent Stories
-
Ainos AI Nose Improves Accuracy in Hygiene Monitoring To 85% from 80%
-
Ainos Showcases Breakthrough AI Nose Technology at COMPUTEX 2025 with Japan's Robotics Partner
-
Ainos (AIMD) signs commercial media agreement with New to The Street
-
AINOS (NASDAQ: AIMD) Signs Long-Form Interview and National TV Commercial Agreement with New to The Street
-
Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy
-
Water Tower Research Highlights Ainos' Significant Commercial Traction and Strategic Milestones Across Multiple Sectors
-
Ainos (AIMD) Misses Q1 EPS by 21c
-
Ainos Reports First Quarter 2025 Financial Results
-
Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Ainos Forms Partnership with ASE's Key Site to Power AI-Driven SmellTech in Semiconductor Smart Manufacturing
-
Water Tower Research Spotlights Ainos' Smell Integration in Humanoid Robot - AI Smelltech is Progressing Rapidly
-
Ainos (AIMD) and ugo Complete First Robotic Smell Integration in Japan
-
Ainos and ugo Complete First Robotic Smell Integration in Japan
-
Ainos Secures TFDA Approval and IRB Clearance to Advance VELDONA Clinical Trials for HIV Oral Warts and Sjögren's Syndrome in Taiwan
-
Water Tower Research Highlights Ainos' AI Nose Expansion into Robotics and Semiconductor Manufacturing - Smell ID Is Scaling
-
Ainos to Participate in Fireside Chat with Water Tower Research on April 8, 2025
-
Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Nose’s Potential in Chip Manufacturing and More
-
Ainos (AIMD) and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing
-
Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing
-
Ainos Reports Full Year 2024 Financial Results
-
Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here
-
Ainos (AIMD) and ugo to Develop a Robot With a Sense of Smell
-
Ainos and ugo to Develop the World's First Robot With a Sense of Smell
-
Ainos (AIMD) Receives Japan Patent Approval for VELDONA Redefines Antiviral Innovation
-
Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation
-
Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025
-
Ainos (AIMD) Granted Nasdaq Extension to Regain Compliance
-
Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule
-
Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots
-
Ainos (AIMD) Files for 6.74M Share Offering by Selling Stockholders
-
CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
-
Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA
-
Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement
-
Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing
-
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug
-
Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments
-
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 20
-
Ainos (AIMD) Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
-
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
-
Ainos Reports Third Quarter 2024 Financial Results
-
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets
-
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast
-
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
-
Ainos (AIMD) Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial
-
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
-
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome
-
Ainos (AIMD) Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
-
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options
-
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
-
Ainos (AIMD) to Initiate Taiwan Clinical Study for VELDONA

